DBV Technologies

Quick facts

Phase 3 pipeline

• DBV712 · Immunology / Allergy
  DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance.
• Viaskin Peanut 250µg · Allergy
  Viaskin Peanut 250µg is an epicutaneous immunotherapy that works by gradually increasing tolerance to peanut allergens.

Phase 2 pipeline

• Viaskin Peanut

Phase 1 pipeline

• DBV712 IHRP
• Viaskin Milk 300 mcg
• Viaskin PT 25 mcg
• Whole peanut extract

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• DBV Technologies portfolio CI brief
• DBV Technologies pipeline updates RSS